Aligos Therapeutics, Inc. Retained Earnings
Aligos Therapeutics, Inc. (ALGS) had Retained Earnings of -$666.75 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:RetainedEarningsAccumulatedDeficit · last filed 2026-08-06
- 2026-06-30: Retained Earnings (Accumulated Deficit) -$666.75M.
- 2026-03-31: Retained Earnings (Accumulated Deficit) -$665.24M.
- 2025-12-31: Retained Earnings (Accumulated Deficit) -$642.20M.
- 2025-09-30: Retained Earnings (Accumulated Deficit) -$622.32M.
| Period end | Retained Earnings (Accumulated Deficit) |
|---|---|
| 2026-06-30 | -$666.75M 10-Q · filed 2026-08-06 |
| 2026-03-31 | -$665.24M 10-Q · filed 2026-05-07 |
| 2025-12-31 | -$642.20M 10-Q · filed 2026-08-06 |
| 2025-09-30 | -$622.32M 10-Q · filed 2025-11-06 |
| 2025-06-30 | -$590.78M 10-Q · filed 2025-08-06 |
| 2025-03-31 | -$574.92M 10-Q · filed 2025-05-06 |
| 2024-12-31 | -$618.01M 10-K · filed 2026-03-05 |
| 2024-09-30 | -$535.86M 10-Q · filed 2024-11-06 |
| 2024-06-30 | -$516.60M 10-Q · filed 2024-08-06 |
| 2024-03-31 | -$521.66M 10-Q · filed 2024-05-07 |
| 2023-12-31 | -$486.80M 10-K · filed 2025-03-10 |
| 2023-09-30 | -$458.90M 10-Q · filed 2023-11-02 |
| 2023-06-30 | -$440.86M 10-Q · filed 2023-08-03 |
| 2023-03-31 | -$422.07M 10-Q · filed 2023-05-04 |
| 2022-12-31 | -$399.12M 10-K · filed 2024-03-12 |
| 2022-09-30 | -$377.23M 10-Q · filed 2022-11-02 |
| 2022-06-30 | -$358.61M 10-Q · filed 2022-08-04 |
| 2022-03-31 | -$338.69M 10-Q · filed 2022-05-04 |
| 2021-12-31 | -$303.07M 10-K · filed 2023-03-09 |
| 2021-09-30 | -$265.36M 10-Q · filed 2021-11-04 |
| 2021-06-30 | -$232.23M 10-Q · filed 2021-08-05 |
| 2021-03-31 | -$202.41M 10-Q · filed 2021-05-10 |
| 2020-12-31 | -$174.74M 10-K · filed 2022-03-10 |
| 2020-09-30 | -$140.32M 10-Q · filed 2020-11-25 |
| 2019-12-31 | -$66.20M 10-K · filed 2021-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| Protara Therapeutics, Inc. (TARA) | United States | $0.198B | -3.22 |